Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment

What is the purpose of this trial?

The purpose of this study is to determine if an investigational treatment (Maribavir) is safe and effective in treating transplant recipient patients with cytomegalovirus (CMV) infections that are refractory or resistant to treatment.


Participation Guidelines

Ages: 12 - 80 years

Gender: Both


Shire ViroPharma, Inc.

Start Date: 01/24/2018

End Date: 05/31/2019

Last Updated: 04/09/2018

Study HIC#: 2000020766

Get Involved

For more information about this study, contact:
Ricarda Tomlin
+1 203-785-2073
ricarda.tomlin@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Maricar Malinis

Principal Investigator

Sub-Investigators